Ryan Specialty CRO Sells at $40: Analysts Targeting $50
Ryan Specialty's co-president and CRO Brendan Mulshine sold $1.62 million in stock at $40.51 in early September, weeks after the company posted a 23.3% earnings beat. Wall Street's consensus price tar
Ryan Specialty CRO Sells $1.6M While Analysts Target $50
NEW YORK, September 19 —
Ryan Specialty Holdings, Inc. (RYAN) finds itself at an unusual impasse: the executive closest to its revenue pipeline sold $1.62 million of stock at $40.51 in early September, weeks after the company posted a 23.3% earnings beat, while Wall Street's consensus price target of $50.53 sits nearly $10 above where he sold. Either the Street is chasing a number that insiders quietly reject, or the company's own revenue chief is leaving material upside unrealized.
- Co-president and CRO Brendan Mulshine sold 40,000 shares at $40.51 on September 8, per SEC filings.
- Q2 2026 EPS of $0.74 beat consensus of $0.60 by 23.3%, per the July 30 8-K.
- Trailing-twelve-month revenues of $3.16 billion, up 7.4% year-over-year; $3.81 billion in total debt against $140 million in cash.
The Selling Pattern Reads Poorly Against the Earnings Tape
Ryan Specialty is a specialty insurance intermediary, a wholesale broker and program administrator connecting retail agents with carriers for complex, non-standard risks, earning fees and commissions without taking underwriting risk onto its own balance sheet. The Chicago-based firm, founded in 2010, has delivered back-to-back earnings beats: a 9.2% upside in Q1 2026, and a 23.3% beat in Q2. The trailing 90-day insider record, however, shows $1.71 million in open-market sales against zero in open-market purchases. The reversal is stark: the company's Executive Chairman purchased 120,000 shares around mid-June 2026, per published reports, before Q2 results landed. The buying stopped when the beat was confirmed.
The RSU Sequence Matters, But Doesn't Explain Away $40.51
Four days before his open-market sale, Mulshine completed two share-conversion transactions of 40,000 shares each on September 4, the standard RSU-vesting-and-conversion sequence that typically precedes a sale. Routine mechanics. But the price at which he chose to sell is harder to dismiss: that level, nearly 20% below the analyst consensus target of $50.53 and within cents of where the CFO's tax-withholding disposition settled in mid-July. Multiple insiders, across different transaction types, have clustered near the $40 level, which either reflects disciplined tax planning or a shared view on where the stock belongs.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RYAN | $10.3B | 16.7x | -25.3% |
| CNM | $7.9B | 12.2x | -16.0% |
| HAYW | $2.8B | 13.4x | -12.5% |
| EQH | $14.7B | 6.0x | -0.2% |
| STEP | $6.0B | 13.6x | -30.8% |
| GSHD | $1.9B | 20.2x | -31.3% |
What Changes the Calculus
The forward checkpoint is the next earnings report. RYAN has now beaten estimates in three of the last four quarters, but the prior miss, $0.45 actual against a $0.49 estimate, shows the trajectory is uneven. If Q3 2026 delivers another double-digit beat, the gap between the $40 insider sale price and the $50.53 consensus target starts to look like a timing error rather than a valuation signal. If it doesn't, Mulshine's exit near $40 will look prescient. Run the free Ryan Specialty Holdings, Inc. deep-dive → to track the numbers as they develop.
Current fundamentals, valuation and filing history for Ryan Specialty Holdings, Inc. (RYAN) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Ryan Specialty's CRO sell stock in September?
Brendan Mulshine, the co-president and chief revenue officer, sold 40,000 shares at $40.51 on September 8. Four days earlier, on September 4, he completed routine RSU-vesting-and-conversion transactions of 40,000 shares each, a standard sequence that typically precedes a stock sale. The timing and price raise questions about insider sentiment regarding the stock's value.
What were Ryan Specialty's Q2 earnings results?
Ryan Specialty posted Q2 2026 earnings per share of $0.74, beating consensus of $0.60 by 23.3%. The company has now beaten estimates in three of the last four quarters, with trailing-twelve-month revenues of $3.16 billion, up 7.4% year-over-year.
What is Wall Street's price target for Ryan Specialty?
Wall Street's consensus price target for Ryan Specialty is $50.53, nearly $10 above the $40.51 price where the CRO sold. Multiple insiders have clustered near the $40 level across different transaction types, which either reflects disciplined tax planning or a shared view on where the stock belongs.
How will the next earnings report matter?
The forward checkpoint is Q3 2026 results. If the company delivers another double-digit beat, the CRO's sale near $40 will look like a timing error. If Q3 disappoints, the $40.51 exit will appear prescient, suggesting the executive had material information the Street had not yet priced in.
Ryan Specialty's Co-president and Chief Revenue Officer sold $1.62 million of stock at $40.51 in early September — weeks after the company posted a 23.3% earnings beat — while the Wall Street consensus price target sits at $50.53, nearly $10 above where the insider sold.